The AP-1 Binding Sites Located in the pol Gene Intragenic Regulatory Region of HIV-1 Are Important for Viral Replication

Our laboratory has previously identified an important intragenic region in the human immunodeficiency virus type 1 (HIV-1) genome, whose complete functional unit is composed of the 5103 fragment, the DNaseI-hypersensitive site HS7 and the 5105 fragment. These fragments (5103 and 5105) both exhibit a phorbol 12-myristate 13-acetate (PMA)-inducible enhancer activity on the herpes simplex virus thymidine kinase promoter. Here, we characterized the three previously identified AP-1 binding sites of fragment 5103 by showing the PMA-inducible in vitro binding and in vivo recruitment of c-Fos, JunB and JunD to this fragment located at the end of the pol gene. Functional analyses demonstrated that the intragenic AP-1 binding sites are fully responsible for the PMA-dependent enhancer activity of fragment 5103. Moreover, infection of T-lymphoid Jurkat and promonocytic U937 cells with wild-type and mutant viruses demonstrated that mutations of the intragenic AP-1 sites individually or in combination altered HIV-1 replication. Importantly, mutations of the three intragenic AP-1 sites led to a decreased in vivo recruitment of RNA polymerase II to the viral promoter, strongly supporting that the deleterious effect of these mutations on viral replication occurs, at least partly, at the transcriptional level. Single-round infections of monocyte-derived macrophages confirmed the importance of intragenic AP-1 sites for HIV-1 infectivity.

[1]  C. Van Lint,et al.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies , 2009, Retrovirology.

[2]  L. Kenner,et al.  Translational regulation mechanisms of AP-1 proteins. , 2009, Mutation research.

[3]  R. Hipskind,et al.  SUMOylation Regulates the Transcriptional Activity of JunB in T Lymphocytes1 , 2008, The Journal of Immunology.

[4]  Shou-Jiang Gao,et al.  Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. , 2008, Virology.

[5]  David G. Castner,et al.  Microplate-based chromatin immunoprecipitation method, Matrix ChIP: a platform to study signaling of complex genomic events , 2008, Nucleic acids research.

[6]  F. Dequiedt,et al.  Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencing , 2007, The EMBO journal.

[7]  M. Fresno,et al.  Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. , 2006, The Journal of general virology.

[8]  R. Sarid,et al.  An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. , 2006, The Journal of general virology.

[9]  K. Jeang,et al.  Role for Akt/Protein Kinase B and Activator Protein-1 in Cellular Proliferation Induced by the Human T-cell Leukemia Virus Type 1 Tax Oncoprotein* , 2006, Journal of Biological Chemistry.

[10]  P. Wei,et al.  Expression of adipose differentiation-related protein (ADRP) is conjointly regulated by PU.1 and AP-1 in macrophages. , 2005, Journal of biochemistry.

[11]  A. Burny,et al.  Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity , 2005, Nucleic acids research.

[12]  R. Hipskind,et al.  Down-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation , 2005, Molecular and Cellular Biology.

[13]  B. Prusty,et al.  Constitutive activation of transcription factor AP‐1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP‐1 activity in HeLa cells by curcumin , 2005, International journal of cancer.

[14]  P. Angel,et al.  AP-1 subunits: quarrel and harmony among siblings , 2004, Journal of Cell Science.

[15]  F. Rivas,et al.  Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. , 2003, Biochemical and biophysical research communications.

[16]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[17]  M. Piechaczyk,et al.  The HBZ Factor of Human T-cell Leukemia Virus Type I Dimerizes with Transcription Factors JunB and c-Jun and Modulates Their Transcriptional Activity* , 2003, Journal of Biological Chemistry.

[18]  F. Barré-Sinoussi,et al.  Fcγ Receptor-Mediated Suppression of Human Immunodeficiency Virus Type 1 Replication in Primary Human Macrophages , 2003, Journal of Virology.

[19]  N. Moolla,et al.  Regulatory elements of hepatitis B virus transcription , 2002, Journal of viral hepatitis.

[20]  V. Kiermer,et al.  Upstream Stimulatory Factors Binding to an E Box Motif in the R Region of the Bovine Leukemia Virus Long Terminal Repeat Stimulates Viral Gene Expression* , 2002, The Journal of Biological Chemistry.

[21]  M. Linial,et al.  Cell-Type-Specific Regulation of the Two Foamy Virus Promoters , 2001, Journal of Virology.

[22]  M. Giacca,et al.  Multiple Modes of Transcriptional Regulation by the HIV‐1 Tat Transactivator , 2001, IUBMB life.

[23]  T. Mizutani,et al.  Identification of SWI·SNF Complex Subunit BAF60a as a Determinant of the Transactivation Potential of Fos/Jun Dimers* , 2001, The Journal of Biological Chemistry.

[24]  F. Kirchhoff,et al.  Transactivation of Naturally Occurring HIV-1 Long Terminal Repeats by the JNK Signaling Pathway , 2000, The Journal of Biological Chemistry.

[25]  D. Gabuzda,et al.  ERK MAP Kinase Links Cytokine Signals to Activation of Latent HIV-1 Infection by Stimulating a Cooperative Interaction of AP-1 and NF-κB* , 1999, The Journal of Biological Chemistry.

[26]  Hii,et al.  Direct evidence that ERK regulates the production/secretion of interleukin‐2 in PHA/PMA‐stimulated T lymphocytes , 1999, Immunology.

[27]  Daniel G. Tenen,et al.  c-Jun Is a JNK-independent Coactivator of the PU.1 Transcription Factor* , 1999, The Journal of Biological Chemistry.

[28]  J. Clements,et al.  Targeting of the Visna Virus Tat Protein to AP-1 Sites: Interactions with the bZIP Domains of Fos and Jun In Vitro and In Vivo , 1999, Journal of Virology.

[29]  K. Jeang,et al.  Modulation of Sp1 Phosphorylation by Human Immunodeficiency Virus Type 1 Tat , 1998, Journal of Virology.

[30]  B. Hoffman,et al.  AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis. , 1998, International journal of oncology.

[31]  C. Vinson,et al.  A general method to design dominant negatives to B-HLHZip proteins that abolish DNA binding. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Van Lint,et al.  Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity , 1997, Journal of virology.

[33]  M. Olive,et al.  A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis* , 1997, The Journal of Biological Chemistry.

[34]  C. Van Lint,et al.  Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway , 1997, Science.

[35]  K. Tomonaga,et al.  Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats , 1996, Journal of virology.

[36]  D. Latchman,et al.  Functional interaction between the HIV-1 Tat transactivator and the inhibitory domain of the Oct-2 cellular transcription factor , 1996, AIDS.

[37]  M. Giacca,et al.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[38]  D. Ganem,et al.  Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnaviral genomes: key role of enhancer II. , 1996, Virology.

[39]  D. Aunis,et al.  Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells , 1995, Journal of virology.

[40]  R. Gaynor,et al.  Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants , 1994, Journal of virology.

[41]  A. Burny,et al.  A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1 , 1994, Journal of virology.

[42]  W. Greene,et al.  Cross‐coupling of the NF‐kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. , 1993, The EMBO journal.

[43]  C. Van Lint,et al.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. , 1993, The EMBO journal.

[44]  R. Davis,et al.  The mitogen-activated protein kinase signal transduction pathway. , 1993, The Journal of biological chemistry.

[45]  I. Screpanti,et al.  Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. , 1993, Molecular endocrinology.

[46]  J. Alwine,et al.  Replication of type 1 human immunodeficiency viruses containing linker substitution mutations in the -201 to -130 region of the long terminal repeat , 1993, Journal of virology.

[47]  P. Howley,et al.  Two AP1 sites binding JunB are essential for human papillomavirus type 18 transcription in keratinocytes , 1992, Journal of virology.

[48]  E. Verdin DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1 , 1991, Journal of virology.

[49]  A. Burny,et al.  The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites , 1991, Journal of virology.

[50]  V. ter meulen,et al.  Transcription factor AP-1 modulates the activity of the human foamy virus long terminal repeat , 1991, Journal of virology.

[51]  J. Alwine,et al.  Analysis of the human immunodeficiency virus long terminal repeat by in vitro transcription competition and linker scanning mutagenesis. , 1991, Gene expression.

[52]  Tony Hunter,et al.  Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity , 1991, Cell.

[53]  A. Burny,et al.  Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Müller,et al.  Asymmetrical recognition of the palindromic AP1 binding site (TRE) by Fos protein complexes. , 1989, The EMBO journal.

[55]  G. Nabel,et al.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Malim,et al.  Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes , 1988, Nature.

[57]  R. Tjian,et al.  Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements , 1987, Cell.

[58]  R. Tjian,et al.  Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40 , 1987, Nature.

[59]  R. Warnke,et al.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. , 1984, Cancer research.

[60]  Arthur Weiss,et al.  The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. , 1984, Journal of immunology.

[61]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[62]  K. Bomsztyk,et al.  Protocol for the fast chromatin immunoprecipitation (ChIP) method , 2006, Nature Protocols.

[63]  H. Herschman Primary response genes induced by growth factors and tumor promoters. , 1991, Annual review of biochemistry.